Skip to main content

Advertisement

Table 4 Clinical endpoints modelled and utility decrements applied

From: Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Health state Utility Source
Ischaemic Heart Disease -0.09 UKPDS Study No.68[16]
Myocardial Infarction -0.055 UKPDS Study No.68[16]
Congestive Heart Failure -0.108 UKPDS Study No.68[16]
Stroke -0.164 UKPDS Study No.68[16]
Blindness in one eye -0.074 UKPDS Study No.68[16]
ESRD -0.305 Lee et al. [42]
Amputation -0.28 UKPDS Study No.68[16]